Delivery Order SPE2DB22D1106-SPE2DB25FFAR5
- Not listed
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity. This is a firm fixed-price delivery order with a ceiling value of $3,763.02 and an ultimate completion date of July 28, 2025. The contract was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $2,625.30 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension in 120 mL quantities, with an ultimate completion date of July 29, 2025. This non-set-aside, firm fixed-price contract was competitively awarded on July 28, 2025, with performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a transaction under the company's...
- The Defense Logistics Agency awarded a delivery order valued at $1,202.16 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (150 mL), a medication used to treat attention deficit hyperactivity disorder. The award was made on July 21, 2025, with a completion date of July 22, 2025, under a firm fixed-price delivery order contract with no set-aside designation. The product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $1,918.40 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities. This is a non-set-aside contract with performance scheduled for completion by August 5, 2025, with the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order represents a child contract executed under...
- The Defense Logistics Agency awarded a delivery order valued at $1,609.51 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml Suspension (180 ml), a pharmaceutical product used in the treatment of attention deficit hyperactivity disorder. This competitively awarded, firm fixed-price delivery order was issued on August 14, 2025, with an ultimate completion date of August 15, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities, valued at $4,567.35. This delivery order represents a firm fixed price, non-set-aside contract utilizing AmerisourceBergen's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency awarded a delivery order valued at $2,391.32 to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 120 ml quantity. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The order will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 12, 2025. AmerisourceBergen Drug Corp, a major...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $5,357.13 to AmerisourceBergen Drug Corp for Quillivant XR oral suspension (150mL, 5mg/mL) on August 11, 2025, with completion scheduled for August 12, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Quillivant XR is a long-acting formulation of methylphenidate used to treat...
- The Defense Logistics Agency awarded a $1,314.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (60ml), with an ultimate completion date of August 1, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $3,274.31 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (60 ml), a pharmaceutical product used in treating attention deficit hyperactivity disorder. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFAR5Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,577.04 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (150 mL) with a completion date of July 31, 2025. This firm fixed-price delivery order, issued on July 30, 2025, represents a competitive award with no set-aside designation. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate headquarters as a major pharmaceutical distributor and healthcare solutions provider. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. The IDC enables the contractor to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, and vaccines. Quillivant XR is a pharmaceutical treatment for attention-deficit/hyperactivity disorder (ADHD), demonstrating the contractor's role in providing neurological and behavioral health medications to federal medical supply chains serving the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 7/30/25 |